CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...3233343536373839404142...39313932»
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Journal, PD(L)-1 Biomarker, Metastases:  First line therapy in stage IV BRAF mutated colorectal cancer. (Pubmed Central) -  Sep 12, 2024   
    Further research is needed to validate these findings and explore the ideal sequencing of therapies. CT doublet
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
    Clinical guideline, Journal:  English Title : Treatment of membranous nephropathy (Pubmed Central) -  Sep 12, 2024   
    Among them, Obinutuzumab, a type II anti-CD20, allows a more profound depletion of B cells compared to Rituximab classically used in clinical routine. To illustrate this point, we present the case of a patient suffering from MN with anti-THSD7A antibodies in whom a clinical and biological improvement was observed with obinutuzumab, after failure of conventional therapies.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca
    Clinical, Journal, HEOR, Checkpoint inhibition, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer. (Pubmed Central) -  Sep 11, 2024   
    The sensitivity analysis results were largely consistent with the base case. From the US and Chinese payer perspectives, adding durvalumab or pembrolizumab to chemotherapy is unlikely to be cost effective in the first-line setting for advanced BTC.
  • ||||||||||  Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
    Review, Journal:  Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review. (Pubmed Central) -  Sep 11, 2024   
    Tumor regression was achieved after seven cycles of envafolimab treatment, and the patient obtained postoperative pathological complete response (pCR). Here, we report a case of MSI-H/dMMR transverse colon cancer, who obtained pCR after neoadjuvant envafolimab (a novel subcutaneous single-domain anti-PD-L1 antibody) with a favorable safety profile, aiming to enhance the experiences of comprehensive diagnosis and treatment of colon cancer.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Byvasda (bevacizumab biosimilar) / Innovent Biologics, Etana, Tecentriq (atezolizumab) / Roche
    Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy. (Pubmed Central) -  Sep 11, 2024   
    Among the different combination therapy groups, atezolizumab plus bevacizumab and sintilimab plus IBI-305 seem to have unique advantages, while head-to-head comparisons are still needed. A comprehensive understanding of the developments, the ongoing clinical trials and the mechanisms of combination of immunotherapy and targeted therapy might lead to the development of new combination strategies and solving current challenges such as the molecular biomarkers, the clinical administration order of drugs and the second-line treatments after combination therapy.
  • ||||||||||  Lunsumio (mosunetuzumab-axgb) / Roche
    Review, Journal:  Mosunetuzumab for the treatment of follicular lymphoma. (Pubmed Central) -  Sep 11, 2024   
    At the same time, it improves outcomes in the evolving landscape of FL management, even in post-CAR-T FL patients. Prognostic factors and targetable mechanisms of resistance need to be explored.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Blinatumomab in the Therapy of Acute B-Lymphoid Leukemia. (Pubmed Central) -  Sep 11, 2024   
    These therapeutic successes have led to FDA approval for refractory/relapsed and MRD-positive B-ALL patients. Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment.
  • ||||||||||  pazopanib / Generic mfg., sunitinib / Generic mfg.
    Journal, Metastases:  Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma. (Pubmed Central) -  Sep 11, 2024   
    In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited...Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib.
  • ||||||||||  Nucala (mepolizumab) / GSK, Rituxan (rituximab) / Roche
    UNRAVELING THE ENIGMA OF ANCA-ASSOCIATED VASCULITIS WITH NEGATIVE MPO AND PR3 (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7084;    
    GPA has a considerable overlap in features with some infections and malignancies, and can present a diagnostic challenge for clinicians. Deciding on the correct diagnosis could be challenging, correlation with relevant clinical history, physical exam findings, laboratory results and collaboration with other specialties are necessary to make the right diagnosis.
  • ||||||||||  Rituxan (rituximab) / Roche
    A FREQUENTLY MISSED DIAGNOSIS: MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA OF THE LUNG (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7065;    
    Pulmonary extranodal marginal zone B-cell lymphoma is an uncommon and often easy to miss disease because patients present with nonspecific clinical and radiographic findings. Key to diagnosing this patient disease was through imaging followed by open lung biopsy, pathology and immunohistochemistry.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    INTRACARDIAC METASTASIS OF SQUAMOUS CELL CARCINOMA (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7063;    
    They may have a range of presentations, from asymptomatic to debilitating embolic phenomena. Treatment involves an interdisciplinary approach but the prognosis is often poor given the advanced nature of the underlying malignancies at time of diagnosis.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
    DUAL CHECKPOINT INHIBITOR: BRENTUXIMAB- AND NIVOLUMAB-INDUCED CYTOKINE RELEASE SYNDROME PRESENTING AS DIABETIC KETOACIDOSIS (Convention Center Exhibit Hall: Rapid Fire Area 2C) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7055;    
    This case demonstrates the need for physicians to have high suspicion of CRS for patients presenting with nonspecific symptoms such as refractory metabolic derangements after recent ICI therapy. Due to the diagnostic challenges and implications of ICI-induced irAEs, there is an increasing need for further research and focus on early recognition and treatment of ICI-induced CRS.
  • ||||||||||  Rituxan (rituximab) / Roche
    RITUXIMAB ROULETTE: LUNG COMPLICATIONS UNVEILED (Convention Center Exhibit Hall: Rapid Fire Area 3C) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7053;    
    Hypersensitivity pneumonitis should be taken into consideration in patients receiving rituximab, given the appropriate clinical and radiographic context. Resolution is possible with discontinuation of rituximab and steroid therapy.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    IMMUNE CHECKPOINT INHIBITOR-INDUCED NONINFLAMMATORY CARDIOMYOPATHY (Convention Center Exhibit Hall: Poster Area 1) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6969;    
    As ICIs become increasingly integral to cancer therapy, our findings underscore the importance of vigilant cardiovascular monitoring and early intervention. Future research should delve into the mechanisms and prevention of ICI-induced noninflammatory cardiomyopathy.
  • ||||||||||  Rituxan (rituximab) / Roche
    ANTISYNTHETASE SYNDROME FOLLOWING COVID BOOSTER: A CASE REPORT (Convention Center Exhibit Hall: Rapid Fire Area 4A) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6921;    
    This case shows that early remission is possible if ASyS is identified early and appropriate treatment is initiated. As such, it is imperative that clinicians perform a thorough history and physical and partner with specialists, such as Rheumatologists and Pulmonologists, to avoid diagnostic delays and disease progression.
  • ||||||||||  Rituxan (rituximab) / Roche
    CENTRAL NEUROGENIC HYPERVENTILATION IN A PATIENT WITH MULTIPLE SCLEROSIS: A CASE REPORT (Convention Center Exhibit Hall: Rapid Fire Area 3D) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6920;    
    Intervention and management require careful monitoring, as the bicarbonate buffer system requires time to achieve homeostasis. Although correcting the underlying cause of CNH is the most beneficial treatment available, monitored treatment of respiratory alkalosis and symptoms with opioids has proven to be a beneficial and temporizing measure.
  • ||||||||||  Rituxan (rituximab) / Roche
    CONNECTING SPECIALTIES IN INTERSTITIAL LUNG DISEASE: A DESCRIPTIVE STUDY EXAMINING PATIENTS SEEN IN A COMBINED PULMONARY AND RHEUMATOLOGY CLINIC (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6784;    
    The AI-ILD clinic was built on the philosophy that a multidisciplinary team approach increases the accuracy of ILD diagnosis and optimizes appropriate management faster than the traditional model of siloed subspecialty care. This study suggests good outcomes of the population treated in the clinic, as indicated by the stability of ILD on CT imaging, stable FVC, reduced prednisone usage per patient, and less frequent hospitalization rates when compared to the general population (which averages around 40%).
  • ||||||||||  Rituxan (rituximab) / Roche
    CASE OF ANCA VASCULITIS CAUSING DIFFUSE LYMPHADENOPATHY REQUIRING TRACHEOSTOMY PLACEMENT (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6635;    
    He was discharged on cyclophosphamide, a steroid regimen, and bronchodilators...Ultimately rituximab therapy was initiated and the patient required temporary tracheostomy placement until better immune suppression could be achieved... The differential considerations for lymphadenopathy should include vasculitides.
  • ||||||||||  Gammagard Liquid (human normal immunoglobulin 10%) / Takeda, Gazyva (obinutuzumab) / Roche, Biogen
    GOING BEYOND ANCHOR BIAS: MIXED FUNGAL INFECTIONS AS A CAUSE OF NONRESOLVING PNEUMONIA (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6536;    
    Accumulating therelevant information with thorough history, examination and maintaining a broad differential diagnosisis the key to counter anchor bias. Further research is warranted to assess the influence of anchor biason physician's decision making and patient's clinical outcome.
  • ||||||||||  Rituxan (rituximab) / Roche
    BEYOND THE NORM: A CASE OF LUPUS PSYCHOSIS (Convention Center Exhibit Hall: Rapid Fire Area 2C) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6486;    
    Our case underscores the need to consider autoimmune conditions like SLE in acute psychosis evaluations, even without apparent systemic symptoms or history. Prompt recognition and treatment of reversible causes can improve outcomes and care.